Skip to main content
Home
Browse by Topic
Issues
Latest Issue
Issue Archive
Special Issues
Web Exclusives
Special Series
Conference Correspondent
ASH 2023 - CLL
Ovarian Cancer Overview
Multimedia
All Videos
Interview with the Innovators
Quick Quiz
Subscribe
Home
Browse by Topic
Issues
Latest Issue
Issue Archive
Special Issues
Web Exclusives
Special Series
Conference Correspondent
ASH 2023 - CLL
Ovarian Cancer Overview
Multimedia
All Videos
Interview with the Innovators
Quick Quiz
Subscribe
What Differentiates Abemaciclib, Ribociclib, and Palbociclib?
Breast Cancer
,
Video
,
SABCS Highlights
Conference Correspondent
Hope S. Rugo, MD
Dr Hope Rugo addresses some of the main differences between the 3 CDK4/6 inhibitors that are FDA-approved in HR-positive metastatic breast cancer.
Related Items
Adding Ribociclib to Endocrine Therapy May Reduce Risk for Recurrence in HR-Positive, HER2-Negative, Early Breast Cancer
By
Patricia Stewart
July 2023 Vol 16, No 4 – Online Only
ASCO 2023 Highlights
,
Breast Cancer
FDA Updates Mammography Regulations in MQSA Final Rule
May 2023 Vol 16, No 3
Breast Cancer
,
Healthcare Policy
Pausing Endocrine Therapy to Become Pregnant Appears Safe for Women with Breast Cancer
By
Patricia Stewart
March 2023 Vol 16, No 2
Breast Cancer
,
SABCS Highlights
First-Line Ribociclib plus Endocrine Therapy Beats Chemotherapy for Advanced Breast Cancer
By
William King
January 2023 Vol 16, No 1
SABCS Highlights